Analyst Scoreboard: 6 Ratings For Cencora
Portfolio Pulse from Benzinga Insights
In the past three months, analysts have provided mixed ratings for Cencora (NYSE:COR), with most being somewhat bullish. The average 12-month price target has slightly decreased to $271.0. Cencora, a leading pharmaceutical wholesaler, shows strong financials with impressive revenue growth and profitability, but carries a high debt-to-equity ratio.
October 07, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cencora has received mixed analyst ratings, with a slight decrease in the average price target to $271.0. The company shows strong financial performance but has a high debt-to-equity ratio, which could pose challenges.
The mixed analyst ratings and slight decrease in price target suggest a neutral short-term impact on Cencora's stock price. While the company's financials are strong, the high debt-to-equity ratio could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100